2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Reliance Global Group, Inc. (EZRA) closed its acquisition of the Oblivus GPU cloud computing platform on November 3, 2026, paying $3,000,000 in cash at closing from cash on hand, with up to $750,000 more in milestone payments that depend on future revenue. The company says Oblivus generated about $1.5 million in revenue for the twelve months ended September 2026, based on unaudited seller records, and that the deal marks its entry into the AI infrastructure market. Shareholders should note that the company has not yet filed the required acquired-business financial statements and pro forma information, and that its trading symbol is set to change to XGPU on November 10, 2026.
Closing payment of $3,000,000 in cash; up to two $375,000 milestone payments tied to average monthly cash revenue of $79,000 and $120,000
Oblivus reported about $1.5 million in revenue for the twelve months ended September 2026, per seller's unaudited records
Consulting agreement with founder Matthew Antoun: $250,000 in cash fees over 12 months, plus stock up to $600,000 subject to Board approval
Trading symbol expected to change from EZRA to XGPU on Nasdaq at the open on November 10, 2026
DoubleVerify said it expects the merger under its August 6, 2026 agreement to close in the fourth quarter of 2026, subject to remaining closing conditions. Under the merger, DoubleVerify will survive as a wholly owned subsidiary of Neptune BidCo US Inc., so shareholders will be affected by the completion timing and terms of the deal.
Merger Agreement dated August 6, 2026, with Neptune BidCo US Inc. (Parent) and Wallace Merger Sub Inc. (Merger Sub)
Company expects closing during the fourth quarter of 2026, subject to satisfaction or waiver of remaining conditions
After the merger, DoubleVerify continues as the surviving corporation and a wholly owned subsidiary of Parent
Filing is made under Regulation FD and restates terms of a previously announced transaction
JBS N.V. agreed to acquire Flora Produtos de Higiene e Limpeza S.A., a Brazilian personal care and household products company, from its controlling shareholder J&F, in a transaction valued at US$542 million including assumed debt. JBS also agreed to buy Canal Rural, a Brazilian agribusiness media company, for R$88.1 million, and both deals are related-party transactions to be paid mainly in JBS Class A shares, which would add to the share count and dilute existing holders.
Flora: R$2.968 billion purchase price (US$542 million enterprise value); equity consideration of US$367 million to be paid in JBS Class A shares and/or BDRs
Canal Rural: R$88.1 million purchase price, paid to J&F in Class A shares; the Ex-99.1 release gives a US$11 million transaction value
Share issuance is based on a reference price of R$66.82916 per share (US$12.20 30-day volume-weighted average), with about 31.4 million treasury shares, or 2.9% of the share count, cited in the market presentation
Both agreements were signed November 9, 2026, and the transactions are expected to close in December 2026, subject to customary closing conditions
Forge Nano Holdings said it completed its merger with HzO, Inc. on November 4, 2026, with HzO surviving as a wholly owned subsidiary. HzO stockholders were issued Forge Nano common stock as consideration, and part of that stock is held back for twelve months to secure post-closing adjustments and indemnification. The filing adds dilution from the new shares, but it does not provide HzO financial results or the effect on Forge Nano's earnings.
Merger consideration is based on a $55.0 million base purchase price, plus or minus closing cash, working capital, indebtedness and expense adjustments, divided by $10.00 per share.
Forge Nano issued 5,772,645 shares at the Effective Time, with 1,533,795 Holdback Shares held back for twelve months.
Shares received by HzO stockholders are locked up until the earlier of six months after the Effective Time or when the stock closes at or above $12.00 for 20 of 30 trading days.
HzO's CFO Jason Savod and President and COO Rachael Lerebours signed employment agreements with Forge Nano effective after the Effective Time.
Valor Energy entered an amendment to its equity transfer agreement with Glorious Star, LLC for the Youngstown Computing Center, changing how the $360,000 deposit is handled and setting a closing deadline. The filing states the remaining purchase price is payable at closing and that any additional power capacity would be a separate transaction requiring its own agreement, which does not affect the closing obligations.
Purchase price is $3,600,000; the $360,000 deposit is now paid directly to the seller after Valor confirms due diligence and its Initial Valuation are satisfactory, replacing escrow
Payment is a generally non-refundable down payment credited toward the price, subject to refund provisions in the amendment
Closing is due by the thirtieth Business Day after the original October 18, 2026 effective date, unless extended in writing
Amendment dated November 3, 2026; filed November 9, 2026 as Exhibit 10.1
ZeroStack Corp. agreed on November 3, 2026 to sell all outstanding shares of its wholly owned subsidiary Phatebo GmbH to New Horizon Pharma B.V. for an aggregate price of €2,150,000. Closing depends on German foreign direct investment clearance and other agreed closing conditions, so the sale is not yet complete. The filing does not state the effect of the sale on ZeroStack's financial results.
Buyer: New Horizon Pharma B.V.; the company owns 100% of Phatebo GmbH before the sale.
Aggregate purchase price: €2,150,000.
Closing requires German foreign direct investment clearance and other closing conditions in the Purchase Agreement.
Purchase Agreement dated November 3, 2026 is filed as Exhibit 10.1.
Park Dental Partners closed its acquisition of the dental services organization supporting Village Family Dental on November 6, 2026, expanding into North Carolina, its fourth state. Base consideration was approximately $39.1 million, including 474,535 restricted shares valued at about $9.2 million, with potential aggregate consideration of up to about $46.0 million including earnouts. The company said the transaction's financial impact, including on 2026 guidance, will be shared with its earnings release on November 12, 2026.
Closed November 6, 2026; the transaction was first disclosed August 10, 2026, and adds 12 practice locations and 47 doctors.
Base consideration of approximately $39.1 million, with up to $4.6 million EBITDA-based contingent consideration and up to $2.3 million employment-contingent consideration.
Credit agreement amended to raise the maximum revolving commitment from $15.0 million to $25.0 million and add the North Carolina subsidiary as a co-borrower.
Company will release earnings November 12, 2026, with a call on November 13, and will address the transaction's impact on 2026 guidance then.
Kustom Entertainment amended its Unit Purchase Agreement to acquire TFL, LLC, extending the outside termination date from October 15, 2026 to December 18, 2026. The amendment also sets expense payment and reimbursement terms for the Sellers, and the closing remains subject to third-party consents, stockholder approvals, and other customary conditions.
Outside termination date moved from October 15, 2026 to December 18, 2026
If the deal does not close by December 18, 2026, Kustom will pay the Sellers' eligible expenses incurred after November 16, 2026
If the agreement is terminated, Kustom will reimburse up to $200,000 of Sellers' costs for an incremental audit within five business days
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
CNH Industrial agreed to form a joint venture with Kobelco Construction Machinery by selling a 70% interest in its Construction Equipment business for $700 million in cash, based on an agreed enterprise value of $1 billion. CNH will keep a 30% stake and says it expects to use the net cash proceeds to reduce debt, but the deal requires regulatory approvals and is expected to close by the end of 2027.
Buyers pay $700 million in cash for 70% of the business, valued at an enterprise value of $1 billion, subject to adjustments
CNH retains a 30% interest in the joint venture, with a three-year lock-up period for each party
Closing is expected by the end of 2027; either party may terminate if closing has not occurred by March 30, 2028
CNH said it will report its 2026 third quarter earnings in a separate announcement the same day
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
Abeona Therapeutics acquired APT-1011, now called ABO-801, a clinical-stage treatment candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in exchange for 4,494,383 common shares valued at $20 million, with no upfront cash. The company also agreed to sell 6,400,000 shares and pre-funded warrants for 1,600,043 shares in a private placement for about $30 million, expected to close November 10, 2026, which will add new shares and dilute existing holders.
Ellodi receives 4,494,383 shares valued at $20 million, based on a 20-day VWAP ending the trading day before the November 6, 2026 closing date, and no upfront cash.
Further payments to Ellodi include $30 million upon FDA approval of a New Drug Application, up to $30 million on sales milestones, and tiered royalties in the low to mid teen percentages.
Private placement of 6,400,000 shares at $3.75 per share plus pre-funded warrants at $3.7499, with Morgan Stanley as sole placement agent and net proceeds for general corporate purposes including ZEVASKYN.
One-third of the upfront shares unlock at each of the 6-, 12- and 18-month anniversaries of closing; resale registration for the private placement shares is due within 15 days after closing.
Charles River Laboratories agreed to acquire the bioanalysis and DMPK operations of Frontage Holdings in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in performance-based payments. The company expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after that, and expects to close in the first half of 2027, subject to shareholder and regulatory approvals.
Purchase price of approximately $470 million in cash, subject to customary closing adjustments, with additional payments of up to $75 million tied to future performance
Acquired businesses represented approximately 40% of Frontage's 2025 revenue of $256.7 million and employ approximately 340 people across two Exton sites
Expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter; to be financed through Charles River's credit facility and available cash
Closing expected in the first half of 2027; Frontage is being taken private by a consortium that includes Tigermed and Dr. Song Li
T3 Defense Inc. completed its acquisition of KeepZone AI Inc. on November 4, 2026, paying by issuing 425,594 shares of common stock to the seller, Nexera Technologies Ltd. An amendment to the purchase agreement raised the purchase price to $1,539,800 and lifted the seller's beneficial ownership limit in the company to 9.9%. The company said the deal was not a significant acquisition, so separate KeepZone financial statements are not required.
Purchase price raised to $1,539,800 under the amendment dated November 4, 2026
425,594 new common shares issued to Nexera Technologies Ltd. as consideration
Seller's beneficial ownership limit in T3 Defense raised to 9.9%
Company states the acquisition was not significant under Item 2.01 of Form 8-K
Kontoor Brands completed the sale of its H.D. Lee Company subsidiary to ABG-Storm LLC, an affiliate of Authentic Brands Group, on November 2, 2026. The company received $750 million in cash at closing, subject to post-closing adjustments, plus up to $250 million in earnout payments tied to the Lee business's performance over five years. The filing says the company anticipates using $400 million for accelerated share repurchases and $50 million for open market repurchases.
Closing date: November 2, 2026; cash at closing of $750 million before post-closing adjustments
Pro forma estimate of cash received after adjustments: approximately $698.2 million
Earnout of up to $250 million over five years; estimated fair value at closing of $77.0 million
Planned use of proceeds: $400 million in accelerated share repurchases and $50 million in open market repurchases
HeartSciences filed an 8-K with supplemental disclosures to its proxy statement for the proposed merger with Fortitude Mining Holdings, a subsidiary of Digital Currency Group. The company received seven demand letters from purported shareholders alleging the proxy omits material information, and says the claims are without merit but is voluntarily adding disclosures to avoid delays and litigation expense. The special meeting remains scheduled for November 19, 2026, so the disclosures do not change the vote timing.
Seven demand letters received from counsel to purported shareholders alleging proxy omissions.
Company denies the allegations and says disclosures are voluntary, made without admitting liability.
Supplemental disclosures include a January 6, 2026 letter of intent with Fortitude and an indicated equity value range for Fortitude of $206.0 million to $428.2 million.
Special Meeting to be held virtually on November 19, 2026, at 10:00 a.m. Eastern Time.
Victory Capital filed an 8-K with supplemental disclosures to its proxy statement for the planned acquisition of First Eagle, which it says it made voluntarily to reduce the risk of litigation delaying the deal. Two stockholder lawsuits and a number of demand letters allege the proxy statement was materially incomplete and misleading, and Victory says those claims are without merit. The company states the supplemental disclosures do not change the consideration or the timing of the November 17, 2026 special meeting.
Base purchase price for First Eagle is $7.03 billion, subject to adjustment, including a reduction for First Eagle's funded debt and other debt-like items.
Share consideration is valued at $2 billion based on $116.26 per share and represents 4.9% of Victory's outstanding common stock after issuance.
Two complaints were filed in New York Supreme Court on October 27 and October 28, 2026, and plaintiffs seek to enjoin the deal or seek rescission or damages.
The special meeting of Victory stockholders is scheduled for November 17, 2026, and the board still recommends voting FOR the proposals.
Roku completed its merger with Fox Corporation on November 6, 2026, becoming a wholly owned subsidiary of FOX. Roku stockholders received $95.30 in cash and 0.9799 of a share of FOX Class A common stock per share, and trading of Roku stock on Nasdaq will halt.
The merger became effective on November 6, 2026, resulting in a change in control.
Stockholders are entitled to $95.30 in cash and 0.9799 of a FOX Class A common stock share per share.
Roku requested the removal of its Class A common stock from listing on Nasdaq.
Roku terminated its existing credit agreement dated September 16, 2024.
Bowman Consulting Group Ltd. completed its merger with Prive Parent, Inc., an affiliate of Bernhard Capital Partners, on November 6, 2026, and is now a wholly owned subsidiary of Parent. Each outstanding share was converted into the right to receive $43.00 in cash, so public shareholders no longer hold stock in the company. The company's common stock is being removed from Nasdaq and deregistered, ending its public reporting.
Each share of common stock converted into the right to receive $43.00 in cash, without interest.
The merger was funded by equity commitments from BCP funds and a debt financing commitment, per the filing.
Nasdaq was asked to suspend trading and withdraw the listing before the market opened on November 6, 2026.
Six directors, including founder Gary Bowman, resigned at the Effective Time; Mark D. Spender, Jonathan Parnell, Joe Boyer and Gary Bowman became directors of the Surviving Corporation.
On November 3, 2026, subsidiary The Andersons Renewables, LLC agreed to acquire Harvestone Low Carbon Partners from Energy Capital Partners for $915 million. The three ethanol plants in North Dakota and Indiana have about 215 million gallons of annual capacity, and the company plans to fund the deal with about $300 million from its revolving credit facility and $615 million of new long-term debt. Closing is expected in the fourth quarter of 2026 or early in the first quarter of 2027, subject to regulatory approvals; the company says the deal is expected to be immediately accretive to earnings per share, but the filing gives no figures for this.
Purchase price of $915 million, with about half attributed to expected 45Z and 45Q tax credit cash flows
Three ethanol plants with about 215 million gallons of annual production capacity, combined platform about 730 million gallons
Financing of about $300 million from the revolving credit facility and $615 million in new long-term debt, with committed financing from U.S. Bank and Farm Credit Mid-America
Expected closing in the fourth quarter of 2026 or early in the first quarter of 2027
Acrivon Therapeutics said it acquired Aqilion AB's oral JAK1 inhibitor ACR-525 (formerly AQ280) and a PKCθ inhibitor preclinical program in an asset purchase, paying an undisclosed cash amount. The company says it has no obligation to make milestone or royalty payments, and a separate agreement ends prior royalty and milestone obligations on ACR-525 owed to LEO Pharma. The filing gives no financial results or deal value, so its effect on shareholders is not quantified.
Acrivon paid undisclosed cash consideration with no future milestone or royalty payments owed to Aqilion
Acrivon, Aqilion and LEO Pharma terminated prior royalty and milestone obligations on ACR-525
Eosinophilic esophagitis is the first potential indication for ACR-525, which is described as Phase 2-ready
Acrivon will host a KOL webcast on November 10, 2026, at 4:00 p.m. ET
Sylvamo entered a put option agreement with Midas Atlantic Partners, backed by The Najafi Companies, for a binding offer to acquire its Europe business. The buyer would take the business with an agreed level of working capital and cash, and Sylvamo would receive 20% of future distributions; no purchase price is stated. The company must complete works council and employee consultations before a final decision, and closing is expected by the end of the first quarter of 2027.
Buyer is Midas Atlantic Partners, in partnership with The Najafi Companies
Sylvamo would receive 20% of future distributions from the business in exchange for the transfer
Final decision follows consultations with works councils and employee representatives
Closing is expected by the end of the first quarter of 2027
ANI Pharmaceuticals entered a 364-day senior bridge credit facility of up to $676 million with JPMorgan Chase Bank, N.A. as administrative agent. The facility will be used to finance its recommended public cash offer for Egetis Therapeutics shares, convertible loan and warrants, valued at about SEK 5.6 billion, or approximately $559.9 million, and to refinance ANI's existing term loans and some Egetis debt, which adds significant borrowing and secured obligations for ANI shareholders.
Facility allows borrowings up to $676 million and matures 364 days after initial funding
Initial margin of 1.75% for ABR loans and 2.75% for adjusted term SOFR loans
Offer price is SEK 11.25 per Egetis share; total value about SEK 5.6 billion, or $559.9 million
Completion requires holders of at least 90% of Egetis shares (fully diluted) to tender and regulatory clearances; undertakings covering 42.2% of shares expire if the offer is not declared unconditional by March 31, 2027
NextEra Energy filed unaudited pro forma combined financial information and Dominion Energy's financial statements for the pending merger, which was agreed on May 15, 2026. The filing estimates total merger consideration at $62.1 billion, based on NEE's $83.71 closing price on October 30, 2026, and shows lower pro forma per-share earnings than NEE's historical figures. The deal still requires several regulatory approvals and other closing conditions, and the company says the pro forma figures are illustrative only.
Each Dominion Energy share converts into $360 million in aggregate cash, plus 0.8138 NEE shares, pro rata
Estimated merger consideration is $62.1 billion, based on about 738 million NEE shares at $83.71
Pro forma nine-month 2026 basic EPS is $4.16, versus NEE's historical $4.84
Closing requires HSR clearance and approvals from FERC, NRC, and the Virginia, North Carolina and South Carolina regulators
Axon Enterprise announced an incremental minority investment of about $1.2 billion in drone maker Skydio, which it expects will raise Axon's fully diluted ownership from about 15% to about 37%. The primary purchase closed on November 5, 2026, and the remaining transactions are expected to close in the fourth quarter of 2026 and first quarter of 2027. The deal adds a large cash outlay and share issuance for Axon, and Axon also becomes Skydio's exclusive public safety distributor in the U.S. and Canada.
Primary purchase closed November 5, 2026: 25,000,000 Series G preferred shares at $10.19617 per share, for about $254.9 million in aggregate.
Total investment is about $1.2 billion, with about $720 million (approximately 60%) expected in cash and the remainder in Axon common stock.
Axon stock issued for the investment is capped at 19.99% of shares outstanding before the primary closing.
Tender offer to begin within ten business days of the primary closing; the Committed Secondary is expected to close in the first quarter of 2027.
Sunrise Realty Trust (SUNS) completed its merger with Southern Realty Trust on November 5, 2026. Southern Realty Trust stockholders received 1.45 SUNS shares and $0.05 in cash from SUNS Manager for each share they held, and SUNS issued 8,464,975 shares, bringing shares outstanding to 21,980,826. The company also amended its management agreement, cutting the incentive fee and hurdle rate and reducing the base management fee, which the filing says benefits all SUNS stockholders, while former Southern Realty Trust holders now own about 38.5% of the combined company.
Merger closed November 5, 2026; each Southern Realty Trust share converted into 1.45 SUNS shares plus $0.05 in cash from SUNS Manager
SUNS issued 8,464,975 shares, resulting in 21,980,826 shares outstanding; former Southern Realty Trust stockholders own about 38.5%
Incentive fee reduced from 20% to 17.5% and hurdle rate from 8.0% to 7.0%; base management fee cut by $250,000 per quarter for four quarters, or $1.0 million in total
Pro forma as of June 30, 2026, the combined company had about $534 million of total assets and about $285 million of book value
On November 2, 2026, American Water, Essential Utilities and certain affiliates filed a Stipulation of Settlement in the New Jersey Board of Public Utilities proceeding on their proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and was posted to the NJBPU website as of November 5, 2026. It remains subject to review and approval by the NJBPU, and the filing does not describe the settlement terms.
Merger Agreement with Essential Utilities entered into October 26, 2025, with Essential Utilities surviving as a wholly owned subsidiary of American Water
Stipulation of Settlement filed in the NJBPU proceeding on November 2, 2026, with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel
Stipulation posted to the NJBPU website as of November 5, 2026, and subject to NJBPU review and approval
PSQ Holdings closed the sale of its EveryLife direct-to-consumer baby products business to FreeHold Brands on November 5, 2026, for total consideration of $5.5 million, subject to customary adjustments. The company says the sale completes its move to a focused payments and consumer financing business, with proceeds intended to strengthen the balance sheet and fund growth.
Consideration: $1.0 million in cash at closing plus a $4.5 million seller note secured by EveryLife assets
Seller note accrues interest at the prime rate from February 1, 2027, with a minimum monthly principal payment of $83,333
Note matures 12 months after closing, with up to two 12-month extensions if the buyer cannot obtain bank financing
Company states it now operates exclusively in payments and consumer financing
LightPath Technologies closed the sale of its wholly owned Chinese subsidiary, LightPath (Zhenjiang) Optical Instrumentation Co., Ltd., effective October 30, 2026, to an entity owned by the subsidiary's incumbent management team. The company says it no longer has any facilities or operations in China, and the former subsidiary will continue to supply products to its U.S. and European commercial customers as a third-party vendor.
Sale closed effective October 30, 2026; LightPath sold 100% of its interest in LPOIZ.
Buyer is an entity owned by LPOIZ's incumbent management team.
China operation's third-party revenue averaged approximately $4.5 million annually across fiscal years 2025 and 2026 and will no longer be consolidated.
LPOIZ will continue to supply LightPath's commercial customers in the U.S. and Europe as a third-party vendor.
Five9 entered into a merger agreement on November 5, 2026, to acquire Level AI, with Level AI becoming a wholly owned subsidiary. The cash price is $325.0 million, subject to customary adjustments, and the company says the deal adds AI capabilities and a new way to reach enterprises. Completion depends on customary closing conditions, and the deal is expected to close in 2026.
Aggregate consideration is $325.0 million in cash, subject to adjustments for Level AI's cash, indebtedness, transaction expenses and net working capital at closing.
Stockholders of Level AI holding enough voting power to approve the deal have signed support agreements, so no further Level AI stockholder approval is required.
Either party may terminate if closing has not occurred by February 5, 2027; neither party must pay a termination fee.
Five9 says the deal is expected to close in 2026, and Centerview Partners LLC is its financial advisor.
Willdan Group completed its acquisition of Mantis Intermediate Holdings, LLC, doing business as Mantis Innovation, on October 30, 2026, for approximately $285 million, subject to post-closing adjustments. The company funded the price with $35.0 million from its revolving credit facility and $250.0 million from a new term loan, and said it will provide updated financial guidance on its third quarter earnings call scheduled for November 5, 2026.
Purchase price of approximately $285 million, subject to customary post-closing adjustments, closed October 30, 2026
Funding: $35.0 million of revolving credit facility borrowings and $250.0 million under a new term loan
New $250.0 million term loan matures May 5, 2030, with terms identical to existing credit facilities
Updated financial guidance to be discussed on the November 5, 2026 third quarter earnings call
Armada Acquisition Corp. III, a special purpose acquisition company, signed a business combination agreement on October 31, 2026 with Brains Bioceutical Corp., a Vancouver-based maker of cannabinoid active pharmaceutical ingredients and drug developer. The deal values Brains at an implied pre-money equity value of approximately $750.0 million, and the combined company is expected to trade on Nasdaq as BAPI, with closing expected in the second quarter of 2027 subject to shareholder and regulatory approvals.
Enterprise value of $750.0 million, with new PubCo shares priced at a $10.20 reference value per share
14,705,882 additional earnout shares held in escrow, released if PubCo shares reach $12.50 or $15.00 volume-weighted average price over a three-year earnout period
Closing expected in the second quarter of 2027, subject to shareholder votes, Form F-4 registration effectiveness, Nasdaq listing approval and regulatory approvals
Combined company expected to be named Brains Therapeutics Corp. and trade on Nasdaq under the ticker BAPI
Dropbox agreed on November 3, 2026 to buy all outstanding equity of Tigris Data Inc., an object storage platform built for AI workloads, for cash consideration of about $350 million, subject to customary price adjustments. The company also launched DBX Agent Cloud, a storage offering that initially provides standalone object storage, and closing is expected in the fourth quarter of 2026 subject to customary conditions.
Cash consideration of approximately $350 million, subject to customary purchase price adjustments
Definitive agreement entered November 3, 2026; closing expected in the fourth quarter of 2026
DBX Agent Cloud starts with S3-compatible object storage; AI features have rolled out to more than 70,000 teams
Initial rollout focuses on eligible Standard and Advanced teams in the US, UK, and Australia; broader availability planned for 2027
BHAV Acquisition Corp, a blank check company, and Nemi Corp., a physical AI and manufacturing company, signed a definitive business combination agreement under which Nemi would become a public company listed on Nasdaq under the ticker NEMI. The deal sets Nemi's pre-money equity value at $400 million and is expected to close in the first quarter of 2027, subject to shareholder, regulatory and other approvals, so BHAV shareholders will vote on it and may redeem their shares.
Nemi's pre-money equity value is set at $400 million, or 40,000,000 shares at $10.00 per share.
Nemi targets a $50 million PIPE at $10.00 per share; with full PIPE funding and no redemptions, about $142.5 million of cash is expected at closing from BHAV's $100 million trust account and the PIPE.
A minimum available closing cash condition of $30 million applies, which the parties may waive.
Closing is expected in the first quarter of 2027; the agreement can be terminated if the deal is not completed by June 20, 2027.
Forge Nano Holdings announced on November 5, 2026 that it has completed its acquisition of HZO, Inc., a Morrisville, North Carolina provider of protective coatings for electronics. The all-stock deal involves about 7.3 million Forge Nano shares, with HZO operating as a wholly owned subsidiary. For shareholders, the filing discloses share issuance and dilution but no financial results or deal value.
Forge Nano acquired all outstanding HZO equity in an all-stock transaction for about 7.3 million common shares, subject to customary post-closing adjustments.
About 5.8 million shares are issued at closing, and about 1.5 million shares are held back for twelve months to secure post-closing adjustment and indemnification obligations.
Net issuance is about 5.1 million shares after accounting for about 2.2 million HZO shares held by HZO before closing.
HZO will operate as a wholly owned subsidiary under the HZO brand, led by President Rachael Lerebours.
First Capital, Inc. (FCAP) signed a merger agreement on November 4, 2026, to acquire First Bancorp of Indiana, Inc. in an all-stock transaction valued at about $33.2 million. The deal is expected to close in the first half of 2027, subject to First Bancorp shareholder approval, regulatory approvals and other customary conditions, so shareholders of both companies will see the terms as the deal moves forward.
Each First Bancorp common share converts into 0.3075 shares of First Capital common stock, a fixed ratio that does not adjust for market price changes.
The $33.2 million value is based on First Capital's 20-day volume-weighted average price of $63.05 as of November 4, 2026.
First Bancorp would owe First Capital a $1.4 million termination fee in specified circumstances.
Michael H. Head, First Bancorp's President and CEO, will join First Capital's board at the Effective Time under a Settlement and Restrictive Covenant Agreement dated November 4, 2026.
InMed Pharmaceuticals completed a 1-for-10 consolidation of its common shares and legally changed its name to Mentari Therapeutics, Inc., effective November 4, 2026, after shareholders approved all items at its annual general and special meeting. Shareholders approved the Nasdaq Share Issuance Proposal tied to the pending merger with Mentari, and the share count falls from about 5,493,735 to about 549,374, with trading under INM expected to resume on a post-consolidation basis on November 5, 2026.
Shareholders approved the Nasdaq Share Issuance Proposal with 97.295% of votes cast in favor (2,615,030 shares), covering shares to be issued in the merger with Mentari Therapeutics.
Consolidation: one post-consolidation common share for each ten pre-consolidation shares, reducing shares outstanding from 5,493,735 to about 549,374.
Common shares expected to trade on The Nasdaq Capital Market under INM from the start of trading on November 5, 2026, with new CUSIP 457637809.
One contingent value right per share is expected to be issued to holders of record at the close of business on November 5, 2026, under a CVR agreement to be entered into by the merger closing date.
Lifecore Biomedical said the U.S. Department of Justice and Federal Trade Commission granted early termination of the HSR Act waiting period on November 4, 2026, satisfying one closing condition of its pending merger with Lifecore Inc. The merger still requires other conditions and approvals, including stockholder adoption of the merger agreement at a special meeting.
Early termination of the HSR Act waiting period granted effective November 4, 2026
Merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. was signed September 27, 2026
Stockholder approval at a special meeting and other closing conditions remain outstanding
Company filed a preliminary proxy statement; a definitive proxy statement is still planned
Black Spade III and Astrum amended their August 27, 2026 business combination agreement so the merged company can list on either the NYSE or Nasdaq, as the parties agree in writing. The filing does not report changes to valuation or other financial terms, so the amendment mainly affects where the combined company would trade if the deal closes.
First BCA Amendment dated November 5, 2026, among Black Spade III, Astrum Space Inc and Astrum Networks Pte. Ltd.
Listing venue options: NYSE (including NYSE American) or Nasdaq (including Nasdaq Capital, Global and Global Select markets), as mutually agreed in writing.
Original business combination agreement was entered into on August 27, 2026; Astrum would merge into Black Spade III, which would survive the merger.
Full amendment is filed as Exhibit 2.1 to the 8-K.
DTE Energy agreed on November 1, 2026 to sell all equity interests in its wholly owned subsidiary DTE Vantage to Velocity BidCo LLC for $2,970,672,573, subject to closing adjustments. DTE Vantage holds primarily renewable energy projects and custom energy solutions for industrial, commercial and institutional customers, so the deal changes the company's business mix, and closing requires regulatory approvals and is expected in mid-2027.
Purchase price is $2,970,672,573, subject to adjustments for cash, debt, working capital, capital expenditures and transaction expenses at closing.
DTE's board unanimously approved the transaction on October 30, 2026.
Buyer would pay a $148,533,628.65 termination fee to DTE under specified circumstances.
Closing is currently expected in mid-2027, and either party may terminate if the deal is not completed by August 1, 2027.
On November 3, 2026, DataMEDS AI terminated its Second Amended and Restated Letter of Intent dated October 19, 2026, effective immediately. The letter of intent covered IP acquisitions, a PharmacyChain license expansion, a controlling stake in Tollo Health, and REBOOT licensing, all to be paid in Company common stock, so shareholders would no longer face the share issuances it contemplated.
Termination notices went to EOS, Scilex, Datavault, HBA, THI and REBOOT on November 3, 2026, effective immediately.
The press release says the Company owes no fees or obligations as a result of the termination and will not issue any shares under the letter of intent.
The REBOOT GLP-1 license dated October 13, 2026 and the Datavault PharmacyChain agreement dated November 24, 2025 remain in full force and effect.
Medicus Pharma Ltd. said its wholly owned subsidiary, Skinject, Inc., entered into a non-binding letter of intent with an undisclosed special purpose acquisition company for a proposed business combination. The letter contemplates a $135 million pre-money enterprise valuation for SkinJect and concurrent equity financing, with Medicus seeking to retain majority economic and voting ownership. The terms are largely non-binding, and the company expects completion, if at all, during the first half of 2027.
Non-binding letter of intent with an undisclosed SPAC; contemplated pre-money enterprise valuation of $135 million for SkinJect
Concurrent equity financing intended to support the SKNJCT-005 study in Gorlin syndrome and preparation of a potential New Drug Application
Medicus intends to retain majority economic and voting ownership; completion anticipated during the first half of 2027 but not assured
Third quarter 2026 financial performance and business update call scheduled for November 9, 2026, at 11:30 a.m. ET
Star Equity Holdings' subsidiary Hudson Talent Solutions completed its asset purchase of Cornerstone RPO, LLC on November 2, 2026, paying $500,000 at closing with additional deferred and contingent payments possible. The filing discloses the deal terms but no financial results for Cornerstone, so shareholders cannot assess its size relative to Star's results from the filing alone.
Hudson Talent Solutions paid $500,000 at closing on November 2, 2026, of which $100,000 is held in escrow for the Sellers' indemnification obligations.
$250,000 of fixed deferred consideration is payable under an unsecured, non-interest-bearing note over 36 monthly installments, absent default.
Up to $1.5 million in earnouts is payable in three $500,000 payments if cumulative legacy-client revenue reaches $6,000,000, $12,000,000 and $20,000,000 within 36 months; each payment is 75% cash and 25% in 10% Series A Cumulative Perpetual
An additional $250,000 may be paid if certain client contracts are legally transferred or certain business is established with Hudson Talent Solutions.
Evommune entered an exclusive license for Hinova Pharmaceuticals' VAV1 degraders, including EVO570, for all indications outside Greater China, paying a $20.0 million upfront cash payment plus warrants valued at $10.0 million. The company also agreed to sell 4,966,889 shares at $6.04 per share in a private placement expected to bring in gross proceeds of about $30 million, and estimates that cash plus these proceeds will fund operations into the second half of 2029.
License: $20.0 million upfront cash and pre-funded warrants for up to 1,262,413 shares, plus up to $150.0 million in development and regulatory milestones and up to $920.0 million in commercial milestones
Private placement: 4,966,889 shares at $6.04 per share, expected gross proceeds of about $30 million, expected to close on or about November 6, 2026
Company estimates pro forma cash of approximately $292.3 million, sufficient into the second half of 2029
Investors must file a Form S-3 resale registration within 60 days of closing
At its November 4, 2026 annual meeting, Rallybio stockholders approved the issuance of Rallybio common stock to Avenzo securityholders under the May 31, 2026 merger agreement, a share issuance the filing says will result in a change of control. Stockholders also approved a reverse stock split at a ratio of 1-for-2 to 1-for-9, a name change to Avenzo Therapeutics, Inc., and an increase in authorized shares. The filing says the board will be reconstituted upon completion of the merger.
Share issuance to Avenzo securityholders approved with 4,506,703 votes for, 15,979 against, 14 abstaining and 267,624 broker non-votes.
Reverse split ratio range of 1-for-2 to 1-for-9 approved; final ratio to be mutually determined by Rallybio and Avenzo.
Authorized common shares to increase from 200,000,000 to 500,000,000; name change to Avenzo Therapeutics, Inc. approved.
Avenzo 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan approved, both effective only upon completion of the merger.
Neogen said it expects regulatory review of its planned sale of its global Genomics business to Zoetis to conclude in early 2027. The deal, first announced March 2, 2026, remains subject to customary closing conditions and regulatory approvals, and Zoetis has offered to divest certain Australian assets to help clear the review. The filing gives no purchase price or financial impact, so shareholders face a longer timeline before the transaction can close.
Neogen agreed on March 2, 2026 to sell its global Genomics business to Zoetis Inc.
The Australian Competition and Consumer Commission and New Zealand Commerce Commission are continuing reviews of the transaction.
Zoetis has offered to divest certain assets in Australia to assist the clearance process.
Neogen expects regulatory review to conclude in early 2027.
Shoals Technologies agreed to merge with Array Technologies, with Shoals becoming a wholly owned subsidiary of Array. Each Shoals share will convert into 1.6931 Array shares, and Shoals shareholders are expected to own about 65% of the combined company's basic shares. Completion requires shareholder and regulatory approvals and is expected in the first quarter of 2027.
Each Shoals share converts into 1.6931 shares of Array common stock.
Shoals shareholders expected to own about 65% of combined basic shares (64.5% fully diluted).
Shoals would pay Array a $40.3 million termination fee in certain circumstances, such as a change in board recommendation.
Brandon Moss, Shoals CEO, will become CEO of the combined company; closing expected in Q1 2027.
Penguin Solutions agreed on November 3, 2026, to sell its Cree LED business, which makes up its Optimized LED segment, to an affiliate of Transom Capital Group in an all-cash deal, with closing expected in the first calendar quarter of 2027. The company said the sale will let it concentrate on data center AI infrastructure and memory, and it reaffirmed its fiscal 2027 outlook, which includes a full year of Cree LED results.
Cree LED is expected to represent approximately 10% of the company's total projected fiscal 2027 net sales.
The filing does not disclose the purchase price.
The company reaffirmed its fiscal 2027 outlook from its October 6, 2026, earnings release and expects to update it after the sale closes.
Joseph Clark, President of Optimized LED, will cease to be an executive officer at closing but is expected to continue working for the business.
Eagle Nuclear Energy entered a binding letter of intent dated October 30, 2026 to acquire all outstanding shares of Noble Plains Uranium (TSXV: NOBL) in exchange for Eagle common stock, at an offer price of CAD $0.125 per share. The definitive agreement is not yet signed, and the filing states there is no assurance the deal will be completed on these terms, so shareholders face a transaction that could change Eagle's share count and resource base.
Offer price of CAD $0.125 per Noble Plains share, a premium of about 92% to the CAD $0.065 TSXV close on October 29, 2026.
Existing Eagle stockholders would hold about 95.22% of Eagle and former Noble Plains shareholders about 4.78%, on an issued and outstanding share basis.
Share issuance is expected not to exceed 5,907,109 shares, or 19.9% of Eagle common stock outstanding before October 30, 2026.
Parties must aim to sign a definitive agreement within 60 days; Eagle agreed to a secured bridge loan of up to CAD $500,000, with CAD $150,000 to be advanced after conditions are met, and a US$400,000 break fee applies in specified circumst
Spectrum Brands said its Empower Brands unit, which it owns jointly with funds managed by Oaktree, delivered a non-binding proposal to acquire all outstanding common equity of Helen of Troy for $37.00 per share in cash, at an implied enterprise value of approximately $1.6 billion. The proposal is not a definitive agreement and would require a definitive agreement, Helen of Troy shareholder approval and regulatory approvals. For Spectrum Brands shareholders, the filing describes a potential large acquisition whose cash consideration would be funded partly by new equity from Spectrum Brands, while Helen of Troy's board has called the increased proposal inadequate.
Proposal price is $37.00 per share in cash, up from $34.00 in the initial proposal on August 19, 2026, and raised on October 12, 2026
Implied enterprise value is approximately $1.6 billion; Empower Brands affiliate owns about 4.5% of Helen of Troy shares
Helen of Troy management called the increased proposal inadequate on October 20, 2026, and its board rejected the initial proposal on September 3, 2026
Financing would come from Empower Brands cash, new equity from Spectrum Brands and Oaktree, and third-party debt; Empower Brands debt would be non-recourse to Spectrum Brands
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.